P275 Platinum compounds (PLcs) added to standard adjuvant or neoadjuvant regimen of doxorubicin plus cyclophosphamide (AC), followed by weekly paclitaxel (wP) in triple negative (TN), HER 2-neu positive (HER 2+) or locally advanced breast cancer (LABC)
Vassilaki, M, Sioulas, A, Tsantekidou, M, Klitsa, A, Desses, N, Georgakopoulos, C, Kosmidis, C, Tsionou, C, Parassiris, V, Xepapadakis, G
Published in Breast (Edinburgh) (2011)
Published in Breast (Edinburgh) (2011)
Get full text
Journal Article
Platinum compounds (PLcs) added to standard adjuvant or neoadjuvant regimen of biweekly doxorubicin plus cyclophosphamide (AC), followed by weekly paclitaxel (wP) in triple-negative (TN), HER2-neu-positive (HER2+), or locally advanced breast cancer (LABC): Preliminary results of a prospective, phase II, nonrandomized study
Vassilaki, M., Sioulas, A., Tsantekidou, M., Klitsa, A., Desses, N., Georgakopoulos, C., Thomou, P., Xepapadakis, G.
Published in Journal of clinical oncology (20.05.2010)
Published in Journal of clinical oncology (20.05.2010)
Get full text
Journal Article